Phase I/II clinical studies in 18 patients with H19 over expressing superficial bladder cancer showed 22% complete response and 44% complete marker tumor ablation or a 50% reduction of the marker lesion after six treatments in which the DTA-H19 (BC–819) vector was administrated intravesically as a complex with polyethyleneimine. Here, H19 is linked to breast cancer.